1.50
-0.02
(-1.32%)
Jun 19 - Close
OTCBB
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 1.40 - 1.55 |
| 52 week | 0.23 - 2.13 |
| Open | 1.40 |
| Vol / Avg. | 42,770.00/25,836.00 |
| Mkt cap | 16.77M |
| P/E | - |
| Div/yield | - |
| EPS | -0.37 |
| Shares | 11.18M |
| Beta | 0.87 |
| Inst. own | 0% |
Events
Mar 25, 2013
Q4 2012 Soligenix, Inc. Earnings Release
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -122.76% | -132.39% |
| Operating margin | -187.84% | -149.16% |
| EBITD margin | - | -141.83% |
| Return on average assets | -80.84% | -64.40% |
| Return on average equity | -104.39% | -80.51% |
| Employees | 10 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite C-10, 29 Emmons Drive
PRINCETON, NJ 08540
United States - Map
+1-609-5388200 (Phone)
+1-609-4526467 (Fax)
PRINCETON, NJ 08540
United States - Map
+1-609-5388200 (Phone)
+1-609-4526467 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Soligenix, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing products to treat the side effects of cancer treatment and gastrointestinal diseases, as well as developing several biodefense vaccines and therapeutics. The Company operates in two business segments: BioTherapeutics and BioDefense. The Company's BioTherapeutics business segment focuses to develop orBec (oral beclomethasone dipropionate( oral BDP)) and other biotherapeutic products, while the Company's collaboration partner, Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) will commercialize orBec and oral BDP in North America and Europe, if approved. The Company's Vaccines/BioDefense business segment includes RiVax, SGX204 and SGX202. As of December 31, 2011, the Company�s products, which were under development, include orBec, SGX201, SGX203, LPM Leuprolide, ThermoVax, RiVax and SGX202. In December 2012, the Company acquired a novel drug technology, known as SGX94.
Officers and directors
| Christopher J. Schaber Ph.D. | Chairman of the Board, President, Chief Executive Officer | |
| Joseph M. Warusz CPA | Acting Chief Financial Officer, Vice President - Finance, Corporate Secretary | |
| Robert N. Brey Ph.D. | Senior Vice President, Chief Scientific Officer | |
| Kevin J Horgan MD | Senior Vice President, Chief Medical Officer | |
| Keith L Brownlie CPA | Independent Director | |
| Gregg A Lapointe CPA | Independent Director | |
| Robert Joseph Rubin M.D. | Independent Director | |
| Jerome B Zeldis M.D., Ph.D. | Independent Director |